Medtronic Inc. (MDT): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Medtronic ( MDT) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.2%. By the end of trading, Medtronic rose $0.59 (1.1%) to $53.51 on average volume. Throughout the day, 6,015,959 shares of Medtronic exchanged hands as compared to its average daily volume of 4,634,600 shares. The stock ranged in a price between $53.10-$53.80 after having opened the day at $53.13 as compared to the previous trading day's close of $52.92. Other companies within the Health Care sector that increased today were: USMD Holdings ( USMD), up 28.1%, Biolase ( BIOL), up 15.4%, Epizyme ( EPZM), up 10.7% and Skystar Bio-Pharmaceutical Company ( SKBI), up 10.4%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. Medtronic has a market cap of $53.5 billion and is part of the health services industry. The company has a P/E ratio of 15.7, below the S&P 500 P/E ratio of 17.7. Shares are up 29.0% year to date as of the close of trading on Friday. Currently there are 9 analysts that rate Medtronic a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Medtronic as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, attractive valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Amicus Therapeutics ( FOLD), down 20.4%, Oramed Pharmaceuticals ( ORMP), down 19.1%, Edap TMS ( EDAP), down 14.9% and Senesco Technologies ( SNTI), down 12.6% , were all laggards within the health care sector with Celgene Corporation ( CELG) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Dow Sinks for Eighth Straight Session; Intel's CEO Departs -- ICYMI

Dow Sinks for Eighth Straight Session; Intel's CEO Departs -- ICYMI

Dow Logs Eighth Straight Drop as Stocks Slump

Dow Logs Eighth Straight Drop as Stocks Slump

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

U.S. Banks Pass Fed 'Stress Test' With Room for Dividends, Buybacks

U.S. Banks Pass Fed 'Stress Test' With Room for Dividends, Buybacks

U.S. Drillers at Mercy of Iran, Saudi Production Spat as OPEC Meeting Begins

U.S. Drillers at Mercy of Iran, Saudi Production Spat as OPEC Meeting Begins